Latest Us Litigation News

Adheris Health's US subsidiary is embroiled in a US$2.3 million legal dispute after terminating a key IT services contract. The outcome remains uncertain, with potential financial impacts yet to be quantified.

Amaero Ltd is set to re-domicile from Australia to Delaware via court-approved schemes, issuing US HoldCo CHESS Depositary Interests to shareholders while maintaining its ASX listing. The move aims to tap into deeper US capital markets and enhance strategic growth opportunities.

Orica Limited posted its strongest half-year EBIT in over 20 years at $512 million, driven by premium product demand and strategic acquisitions including Nelson Brothers. The company also initiated a $100 million cost reduction program and declared a 28.5 cent interim dividend.

Orica Limited has resolved its US litigation with CF Industries by agreeing to a US$169.5 million settlement and is acquiring Nelson Brothers’ explosives business, strengthening its North American operations and boosting earnings.

Noumi Limited reported a 9.0% increase in revenue to $162.4 million for Q1 FY26, driven by strong growth in Dairy and Nutritionals and Milklab plant-based milks, while successfully closing legacy legal matters.

Shine Justice Ltd reported a 4.4% rise in FY25 revenue to $204.4 million, alongside major legal settlements and leadership changes, signaling renewed growth momentum.

Atlas Arteria reported a 32.9% drop in statutory net profit for H1 2025 due to a new French tax, yet achieved solid toll revenue and EBITDA growth, maintaining its 2025 distribution guidance.

Atlas Arteria reported a statutory net profit of $73.3 million for H1 2025, impacted by a new tax, while toll revenues rose 8.1%. The company reaffirmed its 2025 distribution guidance of 40 cents per security, supported by strong free cash flow growth.

Noumi Limited reported a nearly flat Q4 FY25 revenue with mixed segment performances and flagged a net loss for the year amid legacy legal expenses. The company highlights growth in its Milklab brand and export sales while managing significant convertible note obligations.

Noumi Limited reported a 2.8% revenue increase to $141.4 million in Q3 FY25, buoyed by gains in its Dairy and Nutritionals segment, while managing legacy legal costs and maintaining strong cash flow.

Noumi Limited’s Q2 FY25 results reveal a resilient plant-based milks segment driving growth, even as traditional dairy and nutritionals face margin pressures amid a challenging market.